Foghorn Therapeutics Inc. - FHTX Enterprise Value-to-Sales Ratio

Foghorn (FHTX) - corporate logo

Foghorn Therapeutics (FHTX) is pursuing global growth in oncology by expanding the capabilities of gene regulation systems. Synergy with leading pharma behemoths enables the creation of advanced therapies for severe tumors. The EV/Revenue multiple visualizes the current market valuation, where -50.12 captures the current state of the parameter. Future prospects depend on the successful safety validation of targeted protein degraders within the framework of clinical scaling.

Foghorn - FHTX Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

FHTX (Foghorn Therapeutics, Inc.): analytical breakdowns and indicator data

Fundamental valuation:Foghorn Therapeutics FHTX
Product sample of Foghorn Therapeutics Inc.

For Foghorn Therapeutics (FHTX), the EV-to-revenue ratio reflects the market value of the business, including net debt, relative to its operating income. This metric measures the value of tangible assets and intellectual capital, excluding the impact of the financing structure. The calculation is based on the ratio of total enterprise value to annual turnover. In the context of targeted therapy development, this indicator reveals the premium investors are paying for the potential of future clinical successes. The stability of this metric confirms the resilience of the capitalization given its dependence on patent protection.